The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Topical versus Systemic Antimicrobial Therapy for Treating Mildly Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double‐Blinded, Multicenter Trial of Pexiganan Cream
Abstract
BACKGROUND: Topical antimicrobial therapy of infected diabetic foot ulcers can focus on the wound and avoid the adverse effects of systemic anti-infective agents. We compared the efficacy of outpatient treatment using an investigational topical antimicrobial peptide, pexiganan acetate cream, with the efficacy of systemic therapy using an oral fluoroquinolone antibiotic, ofloxacin, for mildly infected diabetic foot ulcers. METHODS: In 2 consecutive, double-blind, controlled trials (study 303 and study 304), we randomized diabetic patients with a mildly infected diabetic foot ulcer to receive the active topical agent or active oral antibiotic, plus a respective inactive placebo. The primary outcome of interest was clinical cure or improvement of the infection. Secondary outcomes included eradication of wound pathogens and wound healing, which was documented by a semiquantitative scoring system. RESULTS: Overall, 835 patients were randomized; those in each treatment arm were similar with regard to demographic and clinical characteristics. Although study 303 failed to demonstrate equivalence, study 304 and the combined data for the 2 trials demonstrated equivalent results (within the 95% confidence interval) for topical pexiganan and oral ofloxacin in clinical improvement rates (85%-90%), overall microbiological eradication rates (42%-47%), and wound healing rates. The incidence of worsening cellulitis (2%-4%) and amputation (2%-3%) did not differ significantly between treatment arms. Bacterial resistance to ofloxacin emerged in some patients who received ofloxacin, but no significant resistance to pexiganan emerged among patients who received pexiganan. CONCLUSIONS: Topical pexiganan might be an effective alternative to oral antibiotic therapy in treating diabetic patients with a mildly infected foot ulcer, and might reduce the risk of selecting antimicrobial-resistant bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Self-citationZasloff, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5449 · Cited by 2,305
Self-citationPathways to Diabetic Limb Amputation: Basis for Prevention
Pecoraro, R. E., Reiber, G. E., & Burgess, E. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.5.513 · Cited by 1,580
Diagnosis and Treatment of Diabetic Foot Infections
Lipsky, B. A., Berendt, A. R., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., LeFrock, J. L., Lew, D. P., Mader, J. T., Norden, C., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424846 · Cited by 1,146
Self-citationRisk Factors for Foot Infections in Individuals With Diabetes
Lavery, L. A., Armstrong, D. G., Wunderlich, R. P., Mohler, M. J., Wendel, C. S., & Lipsky, B. A. (2006) · Diabetes Care · doi:10.2337/dc05-2425 · Cited by 787
Self-citationClassification and Treatment of Chronic Nonhealing Wounds
KNIGHTON, D. R., CIRESI, K. F., FIEGEL, V. D., AUSTIN, L. L., & BUTLER, E. L. (1986) · Annals of Surgery · doi:10.1097/00000658-198609000-00011 · Cited by 543
Lavery, L. A., Armstrong, D. G., Wunderlich, R. P., Tredwell, J., & Boulton, A. J. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1435 · Cited by 495
Lavery, L. A., Armstrong, D. G., Murdoch, D. P., Peters, E. J. G., & Lipsky, B. A. (2007) · Clinical Infectious Diseases · doi:10.1086/511036 · Cited by 386
Self-citationExperimental evolution of resistance to an antimicrobial peptide
Perron, G. G., Zasloff, M., & Bell, G. (2006) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2005.3301 · Cited by 369
Self-citationLipsky, B. A., Itani, K., Norden, C., & the Linezolid Diabetic Foot Infections Study Group (2004) · Clinical Infectious Diseases · doi:10.1086/380449 · Cited by 311
Self-citationAntimicrobial Peptides in Health and Disease
Zasloff, M. (2002) · New England Journal of Medicine · doi:10.1056/nejme020106 · Cited by 296
Self-citationA report from the international consensus on diagnosing and treating the infected diabetic foot
Lipsky, B. A., & The International Consensus Working Group on Diagnosing and Treating the Infected Diabetic Foot (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.453 · Cited by 291
Self-citationLipsky, B. A., Armstrong, D. G., Citron, D. M., Tice, A. D., Morgenstern, D. E., & Abramson, M. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67694-5 · Cited by 271
Self-citationSample size requirements for evaluating a conservative therapy.
Makuch, R., & Simon, R. M. (1978) · PubMed · Cited by 228
Lipsky, B. A., & Stoutenburgh, U. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh531 · Cited by 176
Self-citationAntibiotic Therapy for Diabetic Foot Infections: Comparison of Two Parenteral-to-Oral Regimens
Lipsky, B. A., Baker, P. D., Landon, G. C., & Fernau, R. C. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.643 · Cited by 146
Self-citationMicrobiological profile of infected diabetic foot ulcers
Y.Ge, D. M., Hait, H. I., Lipsky, B. A., ZASLOFF, M. A., & Holroyd, K. J. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00696_1.x · Cited by 142
Self-citationSystematic review of antimicrobial treatments for diabetic foot ulcers
Nelson, E. A., O’Meara, S., Golder, S., Dalton, J., Craig, D., Iglesias, C., & on behalf of the DASIDU Steering Group (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01785.x · Cited by 130
Lamb, H. M., & Wiseman, L. R. (1998) · Drugs · doi:10.2165/00003495-199856060-00011 · Cited by 108
Lio, P., & Kaye, E. T. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.006 · Cited by 102
In Vitro Antimicrobial Activity of MSI-78, a Magainin Analog
FUCHS, P. C., Barry, A. L., & Brown, S. D. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1213 · Cited by 86
Sample size considerations for non-randomized comparative studies
Makuch, R., & Simon, R. M. (1980) · Journal of Chronic Diseases · doi:10.1016/0021-9681(80)90017-x · Cited by 78
Optimising Antimicrobial Therapy in Diabetic Foot Infections
Rao, N., & Lipsky, B. A. (2007) · Drugs · doi:10.2165/00003495-200767020-00003 · Cited by 73
Self-citationSample size requirements for comparing time-to-failure among k treatment groups
Makuch, R., & Simon, R. M. (1982) · Journal of Chronic Diseases · doi:10.1016/0021-9681(82)90051-0 · Cited by 62
Measuring the size of ulcers by planimetry: a useful method in the clinical setting
Öien, R. F., Håkansson, A., Hansen, B. U., & Bjellerup, M. (2002) · Journal of Wound Care · doi:10.12968/jowc.2002.11.5.26399 · Cited by 49
Lio, P., & Kaye, E. T. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.008 · Cited by 34
Andrès, E., & Dimarcq, J. L. (2007) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2006.09.009 · Cited by 32
Cited by
Designing antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Lipsky, B. A., Berendt, A. R., Cornia, P. B., Pile, J. C., Peters, E. J. G., Armstrong, D. G., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis346 · Cited by 1,766
Self-citationAntimicrobial host defence peptides: functions and clinical potential
Mookherjee, N., Anderson, M. A., Haagsman, H. P., & Davidson, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0058-8 · Cited by 1,502
Prevention of Intravascular Catheter-Related Infections
(2021) · Indian Journal of Continuing Nursing Education · doi:10.4103/2230-7354.320831 · Cited by 855
Metadata
- Authors
- Lipsky, B. A., Holroyd, K. J., & Zasloff, M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-15
- Volume
- 47
- Issue
- 12
- Pages
- 1537-1545
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2120883121
- Cited by
- 324
- References
- 27
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.